Health Catalyst (NASDAQ:HCAT) stockholders approved three of four proposals presented at the company’s 2026 annual meeting, including the election of two directors, ratification of the company’s auditor and an advisory vote on executive compensation. A proposal to phase out the company’s classified

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Health Catalyst has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $2.26. The stock also fell short of the S&P 500’s 8.2% gain during that period.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.